RxDoctor Payments Data

Thomas Alexander, MD

Cardiovascular Disease · Corpus Christi, TXNPI 1033191838

Payments from drug & device makers

$94,907in general payments, 2019–2025

Across 914 payments — averaging $103.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$63K
  • Medtronic$14K
  • Boston Scientific$3K
  • Abbott$2K
  • Globus Medical$2K
  • Penumbra, Inc.$2K
  • plus $8K from 44 others

What the payments were for

  • Consulting fees$3000%
  • Speaking & faculty fees$58,10561%
  • Travel & lodging$12,44913%
  • Food & beverage$23,99425%
  • Education$580%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$94,907 in reported general payments places this provider in the 90th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$432,087
Medicare patients
1,219
Services billed
4,983

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban304$304,797
XareltoRivaroxaban258$259,698
FarxigaDapagliflozin Propanediol129$107,179
EntrestoSacubitril/Valsartan67$101,029
MultaqDronedarone Hcl61$71,819
Repatha SureclickEvolocumab21$18,832
BrilintaTicagrelor24$18,076
VascepaIcosapent Ethyl19$12,104
Metoprolol Succinate368$4,215
Ranolazine ErRanolazine50$3,531
Atorvastatin Calcium369$3,516
Ezetimibe97$2,687
Diltiazem 12hr ErDiltiazem Hcl13$2,543
ClopidogrelClopidogrel Bisulfate201$2,320
Rosuvastatin Calcium131$1,980

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$188$304,797304 claims
Johnson & JohnsonXarelto$62,862$259,698258 claims
AstraZenecaFarxiga, Brilinta$461$125,255153 claims
NovartisEntresto$640$101,02967 claims
Sanofi-aventis U.S. LLCMultaq$60$71,81961 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Corpus Christi

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →